Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics (AKRO)
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses now. Class Period: Sep. 13, 2022 – Oct. 9, 2023Lead Plaintiff Deadline: June 25, 2024 Visit: www.hbsslaw.com/investor-fraud/AKRO Contact An Attorney Now: AKRO@hbsslaw.com 844-916-0895 Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action: Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit over allegations it misled investors about a key clinical trial. The lawsuit centers on the SYMMETRY study, designed to evaluate efruxifermin ("EFX"), Akero's lead drug candidate, for treating nonalcoholic steatohepatitis (NASH), a serious liver condition. The crux of the complaint lies in Akero's portrayal of the SYMMETRY study's patient population. In June 2019, the FDA issued guidance discouraging the inclusion of
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)GlobeNewswire
- AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead CaseGlobeNewswire
- AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the FirmPR Newswire
- Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.Accesswire
- AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROPR Newswire
AKRO
Earnings
- 11/13/23 - Miss
AKRO
Sec Filings
- 5/10/24 - Form S-3ASR
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- AKRO's page on the SEC website